1,721,234 research outputs found
Editorial: Obesity and chronic kidney disease: complexities, clinical impact, and challenges in nutritional management
No full text
The hunger hormone ghrelin in cachexia
No full textCachexia is characterized by reduced food intake, muscle and adipose tissue loss associated with increased energy expenditure. Cachexia is highly prevalent and represents one of the main causes of increased morbidity, mortality and reduced quality of life in chronic diseases. Ghrelin plays an important role in stimulating and controlling hunger and maintaining energy homeostasis acting on central nervous system and on peripheral tissues. Most of the studies have been conducted in experimental settings and in cancer and uremic patients, showing interesting results in the treatment of cachexia. Further investigations are mandatory to obtain more definitive and conclusive results. © 2013 Informa UK, Ltd
Results from 3 global surveys: The perspectives of healthcare professionals on cancer cachexia
No full textPerspectives of health care professionals on cancer cachexia: results from three global surveys
No full textBackground: Cachexia has a high prevalence in cancer patients and negatively impacts prognosis, quality of life (QOL), and tolerance/response to treatments. This study reports the results of three surveys designed to gain insights into cancer cachexia (CC) awareness, understanding, and treatment practices among health care professionals (HCPs). Methods: Surveys were conducted globally among HCPs involved in CC management. Topics evaluated included definitions and synonyms of CC, diagnosis and treatment practices, and goals and desired improvements of CC treatment. Results: In total, 742 HCPs from 14 different countries participated in the surveys. The majority (97%) of participants were medical oncologists or hematologists. CC was most frequently defined as weight loss (86%) and loss of appetite (46%). The terms loss of weight and decreased appetite (51% and 34%, respectively) were often provided as synonyms of CC. Almost half (46%) of the participants reported diagnosing CC and beginning treatment if a patient experienced a weight loss of 10%. However, 48% of the participants would wait until weight loss was ≥ 15% to diagnose CC and start treatment. HCPs also reported that 61%-77% of cancer patients do not receive any prescription medication for CC before Stage IV of disease is reached. Ability to promote weight gain was rated as the most important factor for selecting CC treatment. Key goals of treatment included ensuring that patients can cope with the cancer and treatment and have a QOL benefit. HCPs expressed desire for treatments with a more CC-specific mode of action and therapies that enhance QOL. Conclusions: These surveys underscore the need for increased awareness among HCPs of CC and its management
Sympathetic nervous system activity may link hyperphagia and fat deposition in human obesity
No full text[No abstract available
- …
